Clarithromycin in treatment of early Lyme disease: a pilot study.
AUTOR(ES)
Dattwyler, R J
RESUMO
Forty-one patients with erythema migrans were enrolled in an open-labelled pilot study of oral clarithromycin, 500 mg twice daily for 21 days, for the treatment of early Lyme disease. Immediately posttherapy, pretreatment signs and symptoms resolved among 91% of the 33 evaluable patients. At 6 months, all 28 of the evaluable patients were well. Clarithromycin shows promise as an effective agent for the treatment of early Lyme disease and warrants further study.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=163136Documentos Relacionados
- Olfactory impairment in motor neuron disease: a pilot study.
- Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study.
- Efficacy of clarithromycin for treatment of experimental Lyme disease in vivo.
- Alzheimer's disease: a correlative study.
- Treatment of late Lyme disease: a challenge to accept.
